Xentech
Xentech is a science-driven preclinical CRO specialized in PDX models, a human tumour-based in vivo approach for predictive testing of anti-cancer therapies.
Xentech gained an acknowledged experience to support ADCs development with models closely replicating the biological features of human tumors.
The 200+ models panel covers the molecular diversity of clinical diseases for breast, prostate and many other cancer indications.
Our high-standard system of quality management provides robust data for confident progression to clinical phases.
